Related Experiment Video
Updated: Jun 6, 2026

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device
Published on: September 24, 2020
[Using metabolic cytoprotector Remaxol for urgently increased stability towards acute decompression syndrome]
Abstract:
The article deals with evaluation of efficiency of metabolic cytoprotector Remaxol as a medication for urgently increased stability towards acute decompression syndrome at severe degree, studied in experiments on 45 outbred male rabbits. Single intravenous injection of Remaxol relieves oxidant effects of inadequate decompression, lowers number of lethal outcomes due to acute decompression syndrome, increases survival time in the animals.
More Related Videos
Related Concept Videos
Acute Respiratory Failure-III
Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Acute Respiratory Failure-IV
Acute Coronary Syndrome V: Nursing Management

